Evaluation of the efficacy and safety of adalimumab therapy in pediatric patients with Crohn’s disease
Journal Title: Postępy Nauk Medycznych - Year 2015, Vol 28, Issue 11
Abstract
Introduction. Crohn’s disease belongs to the group of inflammatory bowel disease(IBD). Prompt diagnosis and early optimal treatment warrants successful outcome,which is disease remission. Introduction of biological drugs for the treatment of IBD increasedthe efficiency of remission.Aim. The aim of the study was to evaluate the effectiveness of induction and maintenanceremission of the disease and safety of adalimumab therapy in pediatric patients withCrohn’s disease.Material and methods. The study included 9 patients with Crohn’s disease with meanage 7.35 years at diagnosis. All patients were treated in the past with IFX or ADA. To assessthe severity of the disease and the effectiveness of treatment authors used PCDAIscale (Pediatric Crohn’s Disease Activity Index) and value of laboratory tests – ESR, CRP,hemoglobine, hematocrite – during enrolment to therapy, after third dose and after 6 and12 months of treatment. The authors assessed safety of adalimumab therapy by evaluationof adverse events occurring during the drug administration and between doses.Results. 8 patients (89%) achieved induction of remission, 1 patient (11%) didn’t respond tothe treatment, while this is the patient previously treated both IFX and ADA. Regard to adverseevents (AE), the authors did not register any AE during administration of the drug, and thosewhich occurred between doses of the drug were not different from those in a healthy population.Conclusions. Adalimumab therapy allows to induction and maintenance remission.The safety profile of adalimumab in pediatric population is comparable with that seen inthe adult population.
Authors and Affiliations
Dorota Jarzębicka, Joanna Sieczkowska, Grzegorz Oracz, Jarosław Kierkuś
Keywords
Related Articles
- EP ID EP77370
- DOI 10.5604/08606196.1190918
- Views 159
- Downloads 0
Analiza wczesnego chimeryzmu przy użyciu PCR w czasie rzeczywistym jako czynnik rokowniczy choroby przeszczep przeciwko gospodarzowi po allogenicznym przeszczepieniu hematopoetycznych komórek krwiotwórczych
Ocena chimeryzmu dawcy odgrywa znaczącą rolę w rokowaniu pacjentów po allogenicznym przeszczepieniu hematopoetycznych komórek krwiotwórczych (alloHSCT).<br><b>Materiał i metody.</b&...
Przestrzeganie zasad leczenia – czy jest problemem u osób w wieku podeszłym?
Choroby przewlekłe wymagają systematycznej terapii wg wskazań i zaleceń lekarza (compliance) przez długi okres czasu (persistance), czyli przestrzegania procedur długoterminowego leczenia (adherence) w celu minimalizacji...
Comparison of two quantitative methods of microscopic feto-maternal haemorrhage evaluation
<b>Introduction.</b> Quantification of feto-maternal haemorrhage (FMH) is essential for determination of an accurate dose of anti-RhD Ig in immunoprophylaxis of haemolytic disease of foetus an...
SM u osób starszych (SM o późnym początku)
Mianem stwardnienia rozsianego o późnym początku określa się te przypadki choroby, które rozpoczynają się w wieku powyżej 50 roku życia. Z tego typu rozpoznaniem mamy do czynienia w 4-9,6% przypadków. SM o późnym początk...
Breast cancer – where are we standing in 2011?
Breast cancer is one of the major health and social problems in women. Due to the wide application of screening programs and to improvements in treatment, breast cancer mortality in some countries has decreased by more t...